Model: Aged C57B/6 mice (between 18-25 months old) 
Dosage: 5 mg/kg/day of ABT-263 was fed to mice while 50 mg/kg/day of dichloroacetate and metformin were injected. For lifespan, they were administered for five consecutive days, followed by a two-day intermission, then an additional five consecutive days, followed by a 6-week intermission.

The combination of dichloroacetate, metformin, and ABT-263 eliminates cancer cells and age-promoting senescent cells while improving endurance and extending lifespan in mice. 


The study was led by Dr. Irina Conboy (image: berkeley.edu). 

Aging &amp; Longevity

Longevity Medicine’s Peptides Craze: Evidence, Delivery Challenges, and Expert Opinions

Advocates say peptides offer significant benefits against aging, while researchers warn that these claims outpace the evidence.

(Peptides are often injected with a syringe | Harvard Health)

Proponents say peptides offer significant effects against aging, while skeptical scientists say these claims outpace the evidence.

New Framework Uncovers 21 Existing Drugs with Pro-Longevity Potential

A new gene network-based framework predicts the potential of existing drugs to confer pro-longevity effects.

A new gene network-based framework predicts already-approved repurposable drugs that may either confer pro-longevity benefits or age-accelerating effects.

Model: Older adults (60–85 years old) with mild cognitive impairment (MCI) enrolled in a randomized, double-blind, placebo-controlled clinical trial.
Dosage: Participants received one gastro-resistant capsule daily for 180 days, containing either 250 mg of Kluyveromyces fragilis yeast extract, 350 mg of Saccharomyces cerevisiae yeast extract, or a placebo.

Yeast Supplement Improves Cognitive Function in Older Adults with Mild Cognitive Impairment

Daily supplementation with nucleotide-rich yeast extracts improves cognitive performance and mental well-being in older adults with mild cognitive impairment, researchers find. 

Brain &amp; Neurons

Model: Six adults who received intravenous NAD+ and eight adults who received intravenous NR
Dosage: 500 mg of intravenous NAD+ or 500 mg of intravenous NR daily for four consecutive days

Pilot Human Study Supports Safety of NAD+ IV and NR IV Infusions

A Stanford study supports the short-term safety of NAD+ and NR infusion therapies, and participants who received NR infusions exhibited significantly lower HbA1c (a blood test that reflects average blood sugar over two to three months).

(An IV bag containing a solution with NAD+ | Crete Fertility Centre)

A Stanford human trial provides the first data supporting the safety of NAD+ IV and NR IV therapies.

Search Result: Safety

Drug Combo Targets Cancer and Senescent Cells to Prolong the Lifespan of Mice, New Study Shows

Longevity Medicine’s Peptides Craze: Evidence, Delivery Challenges, and Expert Opinions

New Framework Uncovers 21 Existing Drugs with Pro-Longevity Potential

Yeast Supplement Improves Cognitive Function in Older Adults with Mild Cognitive Impairment

Pilot Human Study Supports Safety of NAD+ IV and NR IV Infusions